LUTATHERA Injection General Use Result Survey

Study at a glance

From the registry record, last updated by the sponsor on 22 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title

LUTATHERA Injection General Use Result Survey (Somatostatin Receptor-positive Neuroendocrine Tumor, CAAA601A11401)

ClinicalTrials.gov ID

NCT05844332

Acronym / sponsor ID

CAAA601A11401

Conditions

Somatostatin Receptor-positive Neuroendocrine Tumor

Keywords

LUTATHERA

Study type

Observational

Recruitment status

Completed

Enrolment

347 participants (actual)

Lead sponsor

Novartis PharmaceuticalsIndustry (pharma, biotech, devices)

Study start

17 Dec 2021 (actual)

Primary completion

27 Jun 2024 (actual)

Study completion

27 Jun 2024 (actual)

First posted

6 May 2023 (actual)

Results

Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model

Other

Time perspective

Other

Number of arms

1

Who may qualify

Ages

18 to 99 years

Sex

All

Healthy volunteers

Not accepted

Age groups

Adult, Older adult

Study population

All patients treated with this drug for the following indications during a certain post-marketing period • Indication: Somatostatin receptor-positive neuroendocrine tumor

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Primary outcome

1. Proportion of patients with Renal dysfunction, Myelosuppression, Myelodysplastic syndrome/acute myeloid leukaemia and Hormone release induced crises

   Time frame: Until 40 weeks after the date of the last dose (64 weeks if 4 doses are administered 8 weeks apart).

   To evaluate the safety about Renal dysfunction, Myelosuppression, Myelodysplastic syndrome/acute myeloid leukaemia and Hormone release induced crises after administration of this drug in a real world setting

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

• Official record on ClinicalTrials.govLast updated by the sponsor 22 Dec 2025.
• Link to study resultsLink provided by the sponsor.
• Individual participant dataSharing planned: No

Related trials for Somatostatin Receptor-positive Neuroendocrine Tumor

• RecruitingPhase 1

  Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

  Somatostatin Receptor Positive, NETs

• RecruitingPhase 1

  Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

  Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm

• Active, not recruitingPhase 3

  Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

  Neuroendocrine Tumors

• RecruitingPhase 2

  Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

  Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor

• RecruitingPhase 1/2

  Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

  Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

46 sites in 1 country: see every site and its status.